Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

▤ Summary

Ona Therapeutics raised $86.6 million in an oversubscribed Series B round led by Columbus Venture Partners and Mérieux Equity Partners. The company will use the capital to move ONA-255 toward clinical proof of concept in breast cancer and to advance ONA-389 in colorectal cancer. The financing helps Ona transition from a preclinical company to a clinical-stage biopharmaceutical business. The deal also adds new board members and supports upcoming clinical and regulatory milestones.

$ Funding

▦ Linked Companies